<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Fragile site studies were performed on a total of 126 patients with <z:hpo ids='HP_0001909'>leukemia</z:hpo> and other <z:e sem="disease" ids="C1521860" disease_type="Disease or Syndrome" abbrv="">hematologic disorders</z:e> including <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Compared with an incidence (6.0%) of heritable rare fragile sites in the healthy population, the frequency was not higher in the patient group (3.2%), as a whole </plain></SENT>
<SENT sid="2" pm="."><plain>However, two cases of fra(17)(p12) in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> appeared fourfold larger than expected for this group of patients </plain></SENT>
<SENT sid="3" pm="."><plain>In one case, a homozygous carrier of fra(17)(p12) in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e> was also very rarely expected from its population incidence </plain></SENT>
<SENT sid="4" pm="."><plain>These findings suggested a possible role of rare fragile sites, at least in the etiology of these preleukemic or <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> </plain></SENT>
</text></document>